Gain Therapeutics Virtual KOL Event Announcement
Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering clinical-stage biotechnology firm specializing in allosteric, small-molecule therapies, has recently announced an exciting virtual event titled “Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287.” This event will feature prominent Key Opinion Leaders (KOLs) including Karl Kieburtz, M.D., M.P.H., and Kenneth Marek, M.D., who are esteemed figures in neurology and neurodegenerative research.
Event Highlights
The virtual presentation is scheduled for Tuesday, October 14th, 2025, at 4:00 p.m. EST. It aims to delve into current perspectives on biomarkers and clinical outcome scales relevant to Parkinson’s disease (PD). Recent findings presented by Gain Therapeutics’ Chief Medical Officer, Jonas Hannestad, M.D., Ph.D., at a major international congress shed light on the promising results from a Phase 1b trial involving GT-02287, a potential therapeutic candidate for Parkinson's patients.
Key Findings from GT-02287 Trials
This Phase 1b clinical study has revealed that GT-02287 is generally well tolerated among participants, with no severe adverse events documented to date. Moreover, early results indicate improvements in MDS-UPDRS scores, which measure movement and motor function in individuals with Parkinson's.
Following the formal presentations, there will be an interactive Q&A session, providing participants the opportunity to engage with the KOLs directly.
A Closer Look at the Experts
Karl Kieburtz, M.D., M.P.H.
Dr. Kieburtz has a long history of involvement in clinical research for neurodegenerative diseases. He has an impressive track record, having directed numerous international clinical trials focused on neuroprotective agents for Parkinson's disease. His contributions extend to various advisory roles, including serving on committees for the FDA.
Kenneth Marek, M.D.
As the President and Principal Scientist at the Institute for Neurodegenerative Disorders, Dr. Marek's expertise lies in the identification of biomarkers important for assessing neurodegenerative disease progression. His involvement in significant multi-center international studies like the Parkinson Progression Marker Initiative emphasizes his dedication to advancing research in Parkinson's disease and its early detection.
Understanding GT-02287
GT-02287 is designed for individuals with Parkinson’s disease, capable of addressing the molecular causes of the disorder, including those with mutations in the GBA1 gene. This orally administered small molecule functions as an allosteric modulator of the glucocerebrosidase enzyme, pivotal for cellular health. Initial animal studies have shown that GT-02287 improves motor function and may provide neuroprotective benefits by restoring enzyme activity and reducing neuroinflammation.
Strong evidence from preclinical studies suggests GT-02287 holds potential to not only treat but also modify the progression of Parkinson’s disease.
Future Developments
Currently, GT-02287 is undergoing a Phase 1b clinical trial, focusing on its safety and tolerability over a three-month dosing period. This trial is crucial for ascertaining the drug's effectiveness in improving outcomes for patients with Parkinson’s disease.
Moreover, Gain Therapeutics has received significant early-stage funding support from respected organizations such as The Michael J. Fox Foundation and The Silverstein Foundation, underscoring the therapeutic potential of GT-02287 in managing Parkinson's disease and its associated complications.
About Gain Therapeutics, Inc.
Gain Therapeutics strives to lead in the development of next-generation allosteric therapies. With GT-02287 as a flagship candidate, the company aims not only to treat Parkinson’s disease but also has aspirations for its application in conditions like Gaucher’s disease and Alzheimer’s disease. With a suite of preclinical programs targeting various diseases, Gain Therapeutics is committed to innovation in drug discovery through techniques like their advanced Magellan™ platform, aiming to bring transformative treatments to market.
Frequently Asked Questions
What is the significance of the virtual KOL event?
The event is designed to share insights and data related to GT-02287, a key therapeutic candidate for Parkinson’s disease, with experts in the field.
Who are the featured speakers at the event?
The event features Dr. Karl Kieburtz and Dr. Kenneth Marek, both acclaimed professionals in neurology and neurodegenerative disorders.
What are the main objectives of GT-02287?
GT-02287 aims to restore enzyme function in Parkinson’s patients, potentially slowing disease progression and improving motor function.
What types of trials is GT-02287 currently undergoing?
GT-02287 is currently in a Phase 1b clinical trial assessing its safety and effectiveness in individuals with Parkinson’s disease.
How is Gain Therapeutics funded?
Gain Therapeutics has obtained funding from prominent organizations like The Michael J. Fox Foundation, supporting their research and development efforts.
